References
[1]
Ruiz-Ortega, M.;
Rayego-Mateos, S.; Lamas, S.; Ortiz, A.; Rodrigues-Diez, R.R.(2020). Targeting the progression of chronic kidney
disease. Nat. Rev. Nephrol., 16, 269–288.
[2]
P. Formoso, R.
Muzzalupo, L. Tavano, G. De Filpo, F.P. Nicoletta.(2016).Nanotechnology for the
environment and medicine. Mini Rev. Med. Chem. 16 (8), 668–675.
[3]
G. Oberdo¨rster.(2010)
Safety assessment for nanotechnology and
nanomedicine:concepts of nanotoxicology. J. Intern. Med. 267 (1), 89–105.
[4]
N Nema, R Jain,
SK Sukla, APanday. (2015) J. Nanomed. Drug Nano-particle: a release kinetics.Nanotechnol
6, (1).
[5]
X. Huang, Y. Ma,
Y. Li, F. Han, W. Lin. (2021). Targeted drug delivery systems for kidney
diseasesFront. Bioeng. Biotechnol., 9, Article 683247.
[6]
R.M. Williams,
J. Shah, B.D. Ng, D.R. Minton, L.J.Gudas, C.Y. Park, D.A. Heller. (2015).Mesoscale
nanoparticles selectively target the renal proximal tubule epithelium. Nano
Lett. 15 (4), 2358–2364.
[7]
Sun H, Shi K,
Zuo B et al. (2022).Kidney-Targeted Drug Delivery System Based on
Metformin-Grafted Chitosan for Renal Fibrosis Therapy. Molecular Pharmaceutics;
19:3075–3084.
[8]
Tang W, Panja S, Jogdeo CM et al. (2022).Study
of Renal Accumulation of Targeted Polycations in Acute Kidney Injury.
Biomacromolecules; 23, 2064–2074.
[9]
A Pandey, SK
Shukla, R Jain. (2015). Nanosuspension formulation to improve the dissolution
rate of Clonazepam. International
Journal 3 (4), 588-591.
[10] Pandey, J.; Dubey, R.; Kate, A.; Prasad, B.; Sinha,
A.; Mishra, M.S. (2022). Nanomedicines: A Focus on Nanomaterials as Drug
Delivery System with Current Trends and Future Advancement. Drug Res., 72,
355–366.
[11] SKshukla, S pathak, R jain, A pandey. (2020).Nanocarrier
drug delivery involves targeting druga kinetic approach. Oxidation
communications ,43, (4).
[12] T.C. Ho, C.C. Chang, H.P. Chan, T.W. Chung, C.W. Shu,
K.P. Chuang, T.H. Duh,M.H. Yang, Y.C. Tyan. (2022). Hydrogels: properties and
applications in biomedicine. Molecules 27,(9) 2902.
[13] Jain, K.; Kesharwani, P.; Gupta, U.; Jain, N.K.(2010).
Dendrimer toxicity: Let’s meet the challenge. Int. J. Pharm., 394, 122–142.
[14] Zhou, Y.; Xu, H.; Xu, W.; Wang, B.; Wu, H.; Tao, Y.;
Zhang, B.; Wang, M.; Mao, F.; Yan, Y.; et al.(2013).Exosomes released by human
umbilical cord mesenchymal stem cells protect against cisplatin-induced renal
oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res. Ther,4,34.
[15] Wang, D.W.; Li, S.J.; Tan, X.Y.; Wang, J.H.; Hu, Y.;
Tan, Z.; Liang, J.; Hu, J.B.; Li, Y.G.; Zhao, Y.F.(2021).Engineering of
stepwise-targeting chitosan oligosaccharide conjugate for the treatment of
acute kidney injury. Carbohydr. Polym., 256, 117556.
[16] S.M. Grayson, J.M. Fr´echet. (2001). Convergent
dendrons and dendrimers: from synthesis to applications. Chem. Rev. 101 ,(12) ,3819–3868.
[17] Dolman, M.E.; van Dorenmalen, K.M.; Pieters, E.H.;
Lacombe, M.; Pato, J.; Storm, G.; Hennink, W.E.; Kok, R.J. (2012). Imatinib-ULS-
lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the
treatment of renal diseases. J. Control Release, 157, 461–468.
[18] Zheng, X.P.; Nie, Q.; Feng, J.; Fan, X.Y.; Jin, Y.L.;
Chen, G.; Du, J.W.(2020). Kidney-targeted baicalin-lysozyme conjugate
ameliorates renal fibrosis in rats with diabetic nephropathy induced by
streptozotocin. BMC Nephrol., 21, 174.
[19] Pan, X.; Xie, F.; Xiao, D.; Zhou, X.; Xiao, J. (2020).Design,
Synthesis, and Renal Targeting of Methylprednisolone-Lysozyme. Int. J. Mol.
Sci., 21, 1922.
[20] Engel, J.E.; Williams, M.L.; Williams, E.; Azar, C.;
Taylor, E.B.; Bidwell, G.L.; Chade, A.R. (2020).Recovery of Renal Function
following Kidney-Specific VEGF Therapy in Experimental Renovascular Disease.
Am. J. Nephrol., 51, 891–902.
[21] Song, S.; Hou, X.; Zhang, W.; Liu, X.; Wang, W.; Wang,
X.; Cao, W.; Xia, Y.; Chen, W.; Shi, C. (2022).Specific bFGF targeting of KIM-1
in ischemic kidneys protects against renal ischemia-reperfusion injury in rats.
Regen. Biomater. 9, rbac029.
[22] Ahangarpour, A.; Oroojan, A.A.; Khorsandi, L.;
Kouchak, M.; Badavi, M.(2019). Antioxidant, anti-apoptotic, and protective
effects of myricitrin and its solid lipid nanoparticle on
streptozotocin-nicotinamide-induced diabetic nephropathy in type 2 diabetic male
mice. Iran. J. Basic. Med. Sci., 22, 1424–1431.
[23] Liu, D.; Shu, G.; Jin, F.; Qi, J.; Xu, X.; Du, Y.; Yu,
H.; Wang, J.; Sun, M.; You, Y.; et al. (2020).ROS-responsive chitosan-SS31
prodrug for AKI therapy via rapid distribution in the kidney and long-term
retention in the renal tubule. Sci. Adv., 6, eabb7422..
[24] Wang, D.W.; Li, S.J.; Tan, X.Y.; Wang, J.H.; Hu, Y.;
Tan, Z.; Liang, J.; Hu, J.B.; Li, Y.G.; Zhao, Y.F.(2021). Engineering of stepwise-targeting
chitosan oligosaccharide conjugate for the treatment of acute kidney injury. Carbohydr.
Polym., 256, 117556.